CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Inflammation: A New Target For CAD Treatment and Prevention Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease Temporal trends in percutaneous coronary interventions thru the drug eluting stent era: Insights from 18,641 procedures performed over 12-year period Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease A Special Report From the American Heart Association and American College of Cardiology Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China) Incidence, Treatment, and Outcomes of Coronary Perforation During Chronic Total Occlusion Percutaneous Coronary Intervention ACC临床简报:新型冠状病毒对心脏的影响(2019-nCoV) Correction of a pathogenic gene mutation in human embryos

Clinical Case StudySeptember 18, 2019

JOURNAL:JAMA Cardiol. Article Link

Syncope After Percutaneous Coronary Intervention

Tsushima T, Sahadevan J, Intini A. Keywords: syncope; PCI; clinical case

ABSTRACT


A man in his late 50s with a history of remote coronary artery bypass grafting presented with unstable angina and underwent percutaneous coronary intervention with a drug-eluting stent. He was discharged and prescribed ticagrelor, 90 mg twice daily, in addition to his home regimen of aspirin and metoprolol tartrate. Three months later, he experienced worsening exertional dyspnea and had multiple episodes of syncope. He had no history of syncopal episodes or arrhythmias. His baseline transthoracic echocardiogram results demonstrated normal systolic function and no significant valvular disease. Ambulatory electrocardiogram (ECG) monitoring results showed 31 episodes of high-grade atrioventricular (AV) block (AVB), with ventricular pauses ranging from 3.0 to 13.0 seconds occurring during the day and at night. Among them, 4 episodes were associated with presyncope.